MTL1 Leucoflex

Manufacturer
Maco Productions
Effective date
2025-12-29
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
15
Source
full-release
Hydrated at
2026-05-31 21:53:03

Label at a glance#

ProductMTL1 Leucoflex
Active ingredientSODIUM CITRATE, DEXTROSE MONOHYDRATE, ANHYDROUS CITRIC ACID, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, SODIUM CHLORIDE, MANNITOL, ADENINE
Label structure9 sections

Label contents#

Full prescribing information#

Description

DESCRIPTION SECTION

The Leucoflex MTL1 product consists of a blood collection system with 70mL of CPD for the collecion of 500 +/- 50mL of blood and 110mL of AS-1 Additive Solution. They are supplied with sterile, non-pyrogenic fluid pathways. The product as supplied includes an in-line leukoreduction filter known as Leucoflex MTL1, storage containers for blood components and tubing, a sample diversion pouch (Bactivam), a vacuum tube adapter (Vacuvam), and a protective shield for the used needle (Secuvam).

Representative Product Drawing

Reprsentative Product Drawing
Reprsentative Product Drawing

Intended Use

INTENDED USE OF THE DEVICE

The "Leucoflex MTL1 Leukocyte Reduction Filter for Whole Blood" is intended for the pre-storage leukoreduction of whole blood initiated between 4 and 7 hours after collection if whole blood is stored at ambient temperature, or between 4 and 8 hours of storage at 1 to 6 C. The collection set provides for subsequent preparation of AS-1 Red Blood Cells, Leukocytes Reduced (adenine saline added) and Plasma, Leukocytes Reduced in a closed system.

The AS-1 Red Blood Cells, Leukocytes Reduced and Plasma, Leukocytes Reduced may then be stored for the maximum allowable dating periods.

WARNING

WARNINGS SECTION

  • Avoid contact with sharp objects.
  • DO NOT USE if the overwrap or blood bag system shows any signs of deterioration.
  • DO NOT USE if the solutions are not clear.
  • Dispose of all system components that have been contaminated with blood in a biohazard container as per your institution's SOP.
  • Dispose of all sharps as per your institution's SOP.

CAUTIONS

PRECAUTIONS SECTION

  • Do not fold or squeeze the Leucolex MTL1 filter. Inappropriate handling may adversely affect filtration.
  • Check for kinks in the tubing prior to collection and filtration.
  • Rx only.

The protective shield for needle Secuvam (A) and the vacuum tube adapter Vacuvam (B) features of the collection set aid in the safe collection of vacuum tube samples from the sample diversion pouch Bactivam (C) and the disposal of donor needles after blood collection by providing protection from accidental needlestick.

All or part of this medical device is made of PVC plasticized with DEHP. According to some studies, DEHP could potentially be harmful to the reproductive system of male fetuses. The prescriber is solely responsible for choosing to use this device on women who are either pregnant or breast-feeding, or on young male infants. Nevertheless, DEHP-plasticized PVC is in compliance with the European Pharmacopeia.

Risks linked to the reuse: Septic risk.

All manufacturing processes and all components in contact with the donors, the users and the blood components dedicated to the patients are not made with natural rubber latex.

A.jpgA.jpgB.jpgB.jpgC.jpgC.jpg

COLLECTION AND SAMPLING PROCEDURE

INSTRUCTIONS FOR USE SECTION

Before Donation

1) Peel open the transparent overwrap (D) using the corner flap.

2) Support blood bag system as far as possible below donor arm, ideally on an automated blood mixer.

Note: it is recommended that the primary bag on the mixer lies with the tubing on the lower side of the mixer holding plate.

3) Apply tourniquet or pressure cuff (inflate to approximately 60 mm Hg).

4) Prepare venipuncture site as per your SOP.

5) Ensure that the donor line is not twisted or tangled.

Venipucture

1) Open the needle cap (E1) using the following procedure:

a) Twist the needle cap, thus breaking the seal.

b) Lift the cap off of the needle (E2) in a straight line taking special care not to touch the needle in the process (F). Keep hands behind the needle at all times during set use and disposal.

2) Perform the venipuncture

3) After the needle has been inserted, introduce the Secuvam onto the hub of the needle.

4) Tape the Secuvam onto the donor's arm.

Note: if the Secuvam causes discomfort to the donor or decreases the blood flow because of the angle of the needle, leave the Secuvam on the tubing, behind the needle hub (G) during collection. Secure the needle into the Secuvam at the end of the donation (H).

After Venipuncture

1) Ensure that the clamp between the Bactivam pouch and the donation line is open.

2) Ensure that the Bactivam pouch is held below the level of the venipuncture site, and is supported at all times.

3) Allow blood to run into the Bacivam pouch until the pouch fills (approximately 30ml) (I).

4) Close the red clamp (I1) on the transfer line to the Bactivam pouch, by holding the clamp in one hand and squeezing the two edges together, until it locks (a click my be heard).

Note: the red clamp cannot be opened after it has snapped shut.

5) Break the break-away cannula (I2) on the donor line by holding the cannula in one hand and the plastic Y-junction in the other and snapping the cannula both left and right to ensure a clean break. Allow the donation procedure to continue, ensuring that the blood bag is mixed immediately when blood flows into the primary bag.

Note: This step may be done prior to venipuncture if the Blue Roberts clamp (I3) on the donor line is closed prior to breaking the break-away cannula.

6) If using an automated mixer, open the mixer clamp and start the mixer at this point.

Note: it is recommended that the primary bag on the mixer lies with the tubing on the lower side of the mixer holding plate.

7) After approximately 50 ml of blood enters the primary bag, mix thoroughly (when possible).

Note: Collect the quantity of blood stated on the blood bag label.

Sampling Procedure

Note: this is done during the donation. Avoid air in the collection of sample tubes from the diversion pouch to ensure adequate sample volume and avoid hemolysis.

1) Hold the Bactivam pouch with the Vacuvam below it (J), to ensure good blood flow from the pouch to the sampling device, and no introduction of air into the sampling tubes.

2) Remove the cap of the Vacuvam sampling device, and retain for later use (when possible).

3) Introduce a vacuum sampling tube by holding the barrel of the Vacuvam and directing the sample tube cap directly onto the needle inside the device (J1).

4) Blood is drawn automatically into the sampling tube, stopping at the appropriate volume.

5) When the sample tube stops filling, withdraw the tube, ensuring that the tube is pulled out of the barrel in a straight line.

6) Repeat the sampling procedure steps (3 to 5) with all remaining sampling tubes.

7) When all samples have been taken, replace the Vacuvam cap to prevent accidental access to the interior needle (when possible).

8) Mix the blood in the primary bag regularly (approximately every 100 ml or every minute).

After Donation

1) Once the required volume of blood has been collected, close the red clamp on the donor line (J2), at least 12 inches above the primary bag.

Note: if necessary, place a Hemostat on the collection line just below the Secuvam.

2) Release the pressure cuff or tourniquet, and immediately mix the whole blood in the primary bag.

Note: if the needle was taped to the arm, and not the Secuvam, remove the tape from the needle before pulling the needle into the Secuvam (disregard step 3).

3) Remove the tape holding the Secuvam in place.

4) Remove the needle by gently pulling the needle into the barrel of the Secuvam while supporting the Secuvam with one hand (a click may be heard).

Note: if necessary, step 4 may be done before step 3.

5) Remove and discard the cap (if relevant) from the barrel of the Vacuvam, into an appropriate container.

6) Insert the Secuvam needle protector into the barrel of the Vacuvam sampling device.

7) After removing the blood from the mixer/trip scale, mix the blood unit thoroughly.

8) If the donor line is to be used for quality control, strip the line as per procedure (at least 3 times), heat-seal (place clips) and cut (between the clips), leaving sufficient line for testing purposes.

Note: if it is necessary to strip the donor line, it is recommended to strip within 4 minutes of the end of the donation, in order to avoid introducing clots into the blood bag.

9) Ideally, heat-seal the donor line as close as possible to the pack (~1 inch). Alternatively, place clips close to the blood pack and cut between the clips. Mix thoroughly during and immediately after the procedure.

Note: this is an in-line filter system; there is no need to keep the donor line for cross-matching segments.

10) Remove and discard the donor line (K) with the two red clamps, Bactivam, Vacuvam and Secuvam as per SOP.

Note: the completely protected needle after securing the Secuvam inside the rigid Vacuvam sleeve can be disposed of in general biowaste vs. a sharps container

D.jpgD.jpgE1 and E2.jpgE1 and E2.jpgF.jpgF.jpgG.jpgG.jpgH.jpgH.jpgI1 I2 and I3.jpgI1 I2 and I3.jpgJ1 and J2.jpgJ1 and J2.jpgK.jpgK.jpg

COMPONENT PREPARATION GENERAL

INSTRUCTIONS FOR USE SECTION

1 to 6 C Filtration: Ensure that the whole blood to be filtered at cold temperature has reached 1 to 6 C and has been stored between 4 and 8 hours at 1 to 6 C. The height of the unit for filtration should be 72 to 76 inches.

Ambient (20 to 24 C) Filtration: Whole blood filtration may be initiated at room temperature between 4 and 7 hours after collection. Filtrations performed at ambient temperatures should be completed within eight hours of collection. The height of the unit for filtration should be 55 to 60 inches.

CAUTION:

· Do not fold or manhandle the filters (L).

· Do not apply pressure, either mechanical or human, to increase the flow rate of the filter.

· Units with decreased or extended filtration times may not be adequately leukoreduced, and should be evaluated for residual leukocytes and red blood cell recovery before release. Consult training materials for more information on expected length of filtration times and the applicable hold periods in clinical study data.

· Failure to achieve and maintain a closed system throughout processing results in a product that must be stored at 1 to 6 C and transfused within 24 hours.

· Fresh Frozen Plasma should be prepared between 4 and 8 hours of the whole blood donation.

· Fresh Frozen Plasma should be stored at minus 18 C or colder.

· The AS-1 additive solution must be added to the red blood cells without delay after the separation of the plasma. Whole blood in CPD alone may be stored at 1 to 6 C for up to 21 days.

· The filter has been designed and validated to meet the criteria of a leukoreduction filter for whole blood. The filter's performance must be validated using your facility's standard operating procedure (SOP) on component preparation and handling. Any filtration that fails to meet the filtration specifications established by the facility's validation should be evaluated for residual leukocytes and red blood cell (RBC) recovery after filtration.

Note that unusual attributes such as sickle cell trait, cold agglutinins, blood clotting and gel formation, and poor mixing during collection and processing of components can contribute to the failure of a filtration to meet filtration specifications. Faiure to adequately re-suspend RBC by mixing the whole blood unit thoroughly prior to filtration can result in blocked filters.

L
L

WHOLE BLOOD LEUKOREDUCTION

INSTRUCTIONS FOR USE SECTION

1) Mix the blood well.

2) Suspend the blood bag at a height of 55 to 60 inches if filtering at room temperature (20 to 24 C) or 72 to 76 inches if filtering at cold temperature (1 to 6 C).

3) Break the break-away cannula (M) on the blood bag leading to the Leucoflex MTL1 filter, by bending the cannula with a side-to-side motion.

4) Allow the blood to flow by gravity through the Leucoflex MTL1 filter into the transfer bag.

Note: Determine the status of the filtation as follows: If there is no blood flowing from below the filter, the filter is flat and the filter media is visible on the inlet side, filtration is complete.

5) Ensure there is a temporary clamp between the Leucoflex MTL1 filter and the leukoreduced blood.

6) If required, purge the air from the leukoreduced blood back into the flexible Leucoflex MTL1 filter (the filter will expand), filling the segment tubing with blood.

7) Close the temporary clamp before separating the blood and attached satellites.

8) Heat seal the segment tubing just below the Leucoflex MTL1 filter, and all along the segment tubing between the printed numbers.

Note: Do not strip the tubing below the leukocyte reduction filter. Such stripping may pull leukocytes through the filter.

9) Heat seal and discard the empty collection bag, Leucoflex MTL1 filter, temporary clamp and tubing as per SOP.

Note: Ensure that the temporary clamp is not left on the segment tubing.

10) Centrifuge the blood, satellite bag, and additive solution bag together under conditions designed to produce a separation of plasma and red blood cells.

11) Place the centrifuged blood carefully into a plasma extractor, and gently release the pressure plate.

12) Break the break-away cannula on the blood bag by bending the cannula with a side-to-side motion.

13) Express Plasma into the empty transfer bag. If Cryoprecipitate AHF (Anti- Hemophilic Factor) will be manufactured from this Plasma, put a temporary clamp between the "Y" connector (N) and the plasma bag; otherwise, add a permanent clamp.

14) Break the break-away cannula on the additive solution bag by bending the cannula with a side-to-side motion.

15) Suspend the additive solution (AS-1) bag above the RBC bag so that the additive solution drains completely into the RBC without delay.

Note: The additive solution must be mixed thoroughly with the AS-1 Red Blood Cells, Leukocytes Reduced.

16) Heat seal and disconnect the Plasma, Leukocytes Reduced (and any attached transfer bags) as per SOP. Quality control testing should be performed monthly to demonstrate that the WBC content of the plasma is <5 x 10 6 per container if the Plasma or Cryoprecipitated AHF will be labeled as Leukocytes Reduced.

17) Store the AS-1 Red Blood Cells, Leukocytes Reduced at 1-6 C for up to 42 days.

18) Should Cryoprecipitated AHF be manufactured, process the plasma bag and attached empty transfer bag as per SOP.

Clinical Studies Holding Time, Residual WBC and Percent RBC Recovery

WARNING: If unit is spiked for any reason, storage is limited to 24 hours at 1 to 6 C before transfusion.

Filtration

Temperature

n

Holding Time (Hrs)

Mean (Range)

Residual WBC

(x 10 6/ unit)

Mean +/-SD

Percentage

RBC Recovery

Mean +/-SD

20 to 24 C615.1 (4.1 - 6.7)0.417 +/-0.53391.1 +/-3.0
1 to 6 C305.1 (4.6 - 6.1)0.197 +/-0.13189.9 +/-1.9

NOTE: If either face of the filter remains white, the Whole Blood Unit has not been leucoreduced and must be discarded.

M.jpgM.jpgN.jpgN.jpg

HANDLING OF PORT PROTECTORS

INSTRUCTIONS FOR USE SECTION

1) Using both hands tear the port protector as indicated. (O)

2) Hold down the port protector pieces with one hand. (P)

3) Using the free hand, take the spike and engage into the port. (Q)

4) Twist the spike to secure fully in port. (Q)

O.jpgO.jpgP.jpgP.jpgQ.jpgQ.jpg

Labels: Bag 1 Anticoagulant Citrate Phosphate Dextrose Solution USP; Bag 4 Additive Solution AS-1; Overwrap; Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Anticoagulant Citrate Phosphate Dextrose Solution, USP - Bag 1 Label

Bag 1Bag 1

 

Additive Solution AS-1 - Bag 4 Label

Bag 4Bag 4

OVERWRAP LABEL

Overwrap Label
Overwrap Label

CARTON LABEL

Carton Label
Carton Label

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
MANNITOL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95250459-30e4-45c1-b08a-993044f49109Product name220250805
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
cb89b86a-369e-4204-8910-ae797c503af3Product name120230706
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906Product name720210625
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
a62a50ac-1535-4461-9768-8ae703e2e9fbProduct name120210525
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
d4880ace-a516-8c47-8dfd-73a4ba5887d7Product name220180830
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877Product name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
bc07ef78-e82d-0c19-31f4-31f263780582Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
14498-001-01MTL1 Leucoflex1 in 1 KITKIT115

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ADENINEACTIVE INGREDIENTJAC85A21616
ANHYDROUS CITRIC ACIDACTIVE INGREDIENTXF417D3PSL6
DEXTROSE MONOHYDRATEACTIVE INGREDIENTLX22YL083G6
MANNITOLACTIVE INGREDIENT3OWL53L36A6
SODIUM CHLORIDEACTIVE INGREDIENT451W47IQ8X6
SODIUM CITRATEACTIVE INGREDIENT1Q73Q2JULR6
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEACTIVE INGREDIENT593YOG76RN6
ADENINEACTIVE MOIETYJAC85A21616
ANHYDROUS CITRIC ACIDACTIVE MOIETYXF417D3PSL6
ANHYDROUS DEXTROSEACTIVE MOIETY5SL0G7R0OK6
MANNITOLACTIVE MOIETY3OWL53L36A6
PHOSPHATE IONACTIVE MOIETYNK08V8K8HR6
SODIUM CATIONACTIVE MOIETYLYR4M0NH376

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
14498-00114498-001-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040083-001PHENTERMINE HYDROCHLORIDEPHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0784e616aacf4f…
2026-08-18 06:07:402026-07A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0731067a03dcf5…
2025-08-23 18:47 UTC2025-08A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-076a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-072680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-075bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-071e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-078072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-075c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-075d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-074b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-0787673890dc5c…
2021-03-12 10:30 UTC2021-03A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-075aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-078869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-073f01610625f2…
2019-09-15 20:21 UTC2019-09A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07b00525d2431f…
2019-07-19 19:46 UTC2019-07A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-076a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-071c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-079b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-073f0d92c62455…
2023-05-13 08:27 UTC2023-05A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07053a50430f4f…
2023-01-26 05:58 UTC2023-01A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-073bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-073a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040083-001PHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORAL1997-03-07f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MTL1 LeucoflexANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION WITH AS-1Maco Productions0a0b25d1-8fa1-6cd4-e054-00144ff8d46c2025-12-29WarningsExact identifier
ndc (package): 14498-001-01
ndc (product): 14498-001
ndc11 (package): 14498000101
spl id: 18eb3182-4153-4c8e-96e7-a4f30a8557c4
spl set id: 0a0b25d1-8fa1-6cd4-e054-00144ff8d46c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.